> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Licenses Investigational Antisense Therapy
- URL: https://www.fdaweb.com/pfizer-licenses-investigational-antisense-therapy/
- Published: 2019-10-07T12:00:00.000Z
- Updated: 2026-09-15T01:54:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145179

Pfizer has agreed to license Akcea Therapeutics’ Akcea-AngPtl3-L, an investigational antisense therapy being developed for certain cardiovascular and metabolic diseases. The therapy is designed to reduce the production of angiopoietin-like 3 protein in the liver, a key regulator of triglycerides, cholesterol, glucose and energy metabolism, Akcea says.

In a Phase 1/2 study, patients treated with Akcea-AngPtl3-L recorded robust, dose-dependent reductions of triglycerides, LDL-cholesterol and total cholesterol with a positive safety and tolerability profile, Akcea says. It is currently being evaluated in a Phase 2 study in patients with Type 2 diabetes, hypertriglyceridemia and non-alcoholic fatty liver disease.

Under terms of the agreement, Akcea will receive a $250 million upfront license fee from Pfizer. Akcea is also eligible to receive development, regulatory and sales milestone payments of up to $1.3 billion.